DXD Monoclonal Antibody | anti-DXD antibody

DXD Monoclonal Antibody

Cat. Num. AAA278950

• Applications: ELISA
• Purity: Affinity-chromatography
• Synonyms: DXD, Antibody; DXD Monoclonal Antibody; Exatecan derivative; anti-DXD antibody

• Clonality: Monoclonal
• Isotype: IgG2a
• Clone Number: 8D12C11
• Purity/Purification: Affinity-chromatography
• Form/Format: Liquid

• Applicable Applications for anti-DXD antibody: ELISA
• Immunogen: DXD-BSA conjugate
• Buffer: Preservative: 0.03% Proclin 300. Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
• Preparation and Storage: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Application Data

(The purity of Mouse Anti-DXD Antibody is more than 90% by SEC-MALS.)

ELISA

(The Binding Activity of T-DXd(DS-8201) with Anti-DXD antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized T-DXd(DS-8201) at 2 ug/mL can bind Anti-DXD antibody, the EC50 is 2.225 to 2.851 ng/mL.)

ELISA

(The Binding Activity of ADC-2(DXD) with Anti-DXD antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized ADC-2(DXD) at 2 ug/mL can bind Anti-DXD antibody, the EC50 is 2.365 to 2.835 ng/mL.)

ELISA

(The Binding Activity of ADC-1(DXD) with Anti-DXD antibody. Activity: Measured by its binding ability in a functional ELISA. Immobilized ADC-1(DXD) at 2 ug/mL can bind Anti-DXD antibody, the EC50 is 1.840 to 2.253 ng/mL.)

WB (Western Blot)

(DXD antibody on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 90%.)

Related Product Information for anti-DXD antibody

The DXD monoclonal antibody is created using the hybridoma technique. Immunizing a mouse with DXD-BSA induces antibody production by B cells. B cells are extracted from the mouse and then fused with myeloma cells to form hybridomas, from which DXD-specific antibody-producing ones are screened. Selected hybridomas are cultured to generate DXD monoclonal antibodies, which are harvested and subjected to affinity chromatography purification. The purity of the antibody exceeds 90% by SEC-MALS. The antibody's activity has been validated in different functional ELISA, showing the EC50 of 1.840 to 2.253 ng/mL, 2.365 to 2.835 ng/mL, 2.225 to 2.851 ng/mL with ADC-1 (DXD), ADC-2 (DXD), T-DXd (DS-8201), respectively. This DXD monoclonal antibody is a potent tool for DXD-based ADC research, especially for positive reference of DXD-ADC preclinical/clinical immunogenicity, PK analysis, and qualitative detection of DAR value, helping to evaluate and control the efficacy and safety of DXD-ADC drugs.

The Exatecan derivative DXD (deruxtecan) is a cytotoxic payload used in the DXD-ADC (antibody–drug conjugate) technology, an innovative strategy in the field of targeted drug delivery particularly for cancer therapy. DXD-ADC is directed to targeted tumor cells via antibody-tumor cell-sepcific antigen interaction. After that, ADC undergoes internalization and subsequent processing, leading to the release of the cytotoxic DXD. DXD inhibits topoisomerase I (TOP1) activity and leads to the apoptosis of targeted cancer cells. DXD shows 10-fold higher DNA TOP1 activity inhibitory potency than the active metabolite of irinotecan SN-38. Due to its high cell membrane permeability, DXD exerts a bystander antitumor effect, also providing efficient killing of heterogeneous tumor cells. DXD can reduce cross-resistance, has good water solubility, and can form a stable high-DAR (drug-to-antibody ratio) value in ADC for each target. DXD also has a relatively short systemic half-life in the blood and can be excreted faster outside the body, which helps reduce the risk of adverse reactions.